2024-04-09 16:00Investment Rating - The report maintains a "Buy" rating for China Biopharmaceutical (1177.HK) with a target price raised to HKD 5.1 from HKD 4.5, indicating a potential upside of 80% from the current price of HKD 2.8 [3][4]. Core Insights - The strategic collaboration with Boehringer Ingelheim (BI) to develop and commercialize three clinical-stage oncology assets in mainland China is a significant positive development, showcasing the recognition of the company's strong commercialization capabilities [2]. - The three clinical assets are expected to complement the existing pipeline, with a potential peak sales estimate of RMB 5 billion, reflecting the management's confidence in achieving synergies [2]. - The report highlights the potential for further collaborations with BI beyond the initial three assets, indicating a promising outlook for the company's growth in the oncology sector [2]. Financial Performance and Projections - Revenue projections for China Biopharmaceutical are as follows: - 2022: RMB 26,026 million - 2023: RMB 26,199 million (0.7% YoY growth) - 2024E: RMB 29,618 million (13.0% YoY growth) - 2025E: RMB 32,500 million (9.7% YoY growth) - 2026E: RMB 35,888 million (10.4% YoY growth) [9]. - Net profit projections are: - 2022: RMB 2,544 million - 2023: RMB 2,332 million - 2024E: RMB 2,727 million (17% YoY growth) - 2025E: RMB 3,011 million (10% YoY growth) - 2026E: RMB 3,460 million (15% YoY growth) [9]. - The report anticipates a gross margin improvement, with gross profit margins projected to be around 82% in the coming years [9]. Market Position and Valuation - The total market capitalization of China Biopharmaceutical is approximately HKD 53,207 million [4]. - The report estimates the valuation of the BI collaboration pipeline at around RMB 9 billion, based on a peak sales assumption and a success rate [2]. - The price-to-sales (P/S) ratio is projected to decrease from 1.7 in 2022 to 1.2 by 2026, indicating a favorable valuation trend as revenues grow [9].